Smart Immune’s Path To Unlocking The Underappreciated Thymus
ProTcells Can Be Differentiated In Just Seven Days
Executive Summary
French-founded biotech Smart Immune has made significant headway in stimulating the thymus, a small gland with a huge immunological impact which rarely finds itself as a key clinical target. The company is now investigating the impact that two of its ProTcell products in patients with severe combined immunodeficiency and leukemia could have.
You may also be interested in...
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
All About Unlocking Eve: The Initiative Advancing Women In Healthcare Leadership
In Vivo's Chloe Kent discussed the future of women in healthcare leadership with Roche executives and Unlocking Eve founders Eva McLellan and Kaye Vitug.
Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.